Excretion Balance and Urinary Metabolic Pattern of [3H] Cabergoline in Man
- 1 September 1992
- journal article
- research article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 10 (3) , 199-212
- https://doi.org/10.1515/dmdi.1992.10.3.199
Abstract
After oral administration of [3H]cabergoline to man at a single nominal dose of 0.6 mg/subject radioactivity is mainly eliminated by the faecal route (72% of the dose after 10 days). Urine contains 18% of the dose after the same period. The unchanged drug and metabolites present in urine were identified by comparison with reference compounds and quantified by radio-TLC analysis. Cabergoline is extensively metabolized. Unchanged drug in 0-24 h urine represents less than 14% of urinary radioactivity, reaching 20% in 0-96 h urine. The acid derivative FCE 21589 is the main metabolite, amounting to 38% and 30% of the urinary radioactivity in 0-24 h and 0-96 h urine, respectively. The amide derivative FCE 21590 appears to be present in only a small amount, accounting for no more than 4% of the urinary radioactivity in the urine of the first 24 hours after administration and increasing to about 8% in the 0-96 h urine.Keywords
This publication has 12 references indexed in Scilit:
- Syntheses of tritium and carbon-14 labelled N- (3-dimethyl aminopropyl) -N-(ethylaminocarbonyl)-6-(2-propenyl)ergoline-8β-carboxamide (cabergoline), a potent long lasting prolactin lowering agentJournal of Labelled Compounds and Radiopharmaceuticals, 1991
- In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphineEuropean Journal of Pharmacology, 1990
- The metabolism of eugenol in manXenobiotica, 1990
- Long-Lasting Prolactin-Lowering Effect of Cabergoline, A New Dopamine Agonist, in Hyperprolactinemic PatientsJournal of Clinical Endocrinology & Metabolism, 1986
- More on nomifensineJournal of Endocrinological Investigation, 1985
- Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidineEuropean Heart Journal, 1985
- Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolismEuropean Journal of Drug Metabolism and Pharmacokinetics, 1983
- Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitroBiochemical Pharmacology, 1978
- Physiologic disposition of lergotrileClinical Pharmacology & Therapeutics, 1978
- The colour reactions of the hydroxyskatolesJournal of Chromatography A, 1965